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Background: Bronchial artery revascularization (BAR) during lung transplantation has been hypothesized
to improve early tracheal healing and delay the onset of bronchiolitis obliterans syndrome (BOS). We aimed
to assess the outcomes of BAR after lung transplantation.
Methods: Electronic search in Ovid Medline, Cumulative Index of Nursing and Allied Health Literature
(CINAHL), Scopus, and Cochrane Controlled Trials Register (CCTR) databases was performed to identify
all relevant studies published about lung transplantation with BAR. Studies discussing lung transplantation
utilizing BAR were included while those without outcome data such as BOS and survival were excluded.
Cohort-level data were extracted and pooled for analysis. A binary outcome meta-analysis of proportions
with logit transformation was conducted. Newcastle-Ottawa scale was used for risk of bias assessment.
Results: Seven studies were selected for the analysis comprising 143 patients. Mean patient age was 47 (95%
CI: 40–55) years. Sixty-one percent (48–72%) were male. Seventy-three percent (65–79%) of patients underwent
double lung transplant while 27% (21–25%) underwent single lung transplant. In patients with postoperative
angiography, successful BAR was demonstrated in 93% (82–97%) of all assessed conduits. The 30-day/in-hospital
mortality was 6% (3–11%). Seventy-nine percent (63–89%) of patients were free from rejection at three months.
Eighty-three percent (29–98%) of patients were free from signs of airway ischemia at three and six months. Pooled
survival at one year and five years was 87% (78–92%) and 71% (46–87%), respectively, with a mean follow-up
time of 21 (3–38) months. Pooled freedom from bronchiolitis obliterans was 86% (77–91%) at two years.
Conclusions: While this systematic review and meta-analysis is limited by the available surgeons,
institutions, and papers discussing a highly specialized technique, it does show that BAR is a viable technique
to minimize BOS and early anastomotic intervention following lung transplantation.
Keywords: Lung transplant; bronchial artery revascularization (BAR); bronchiolitis obliterans syndrome (BOS)
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Introduction

transplantation following over 55,000 cases from 250 lung

Lung transplantation has been the standard of care for the
treatment of end-stage chronic respiratory failure with the
registry of the International Society for Heart and Lung

transplant centers since the 1990s (1). The United States
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performed 2,562 lung transplantations in 2018 alone
contributing to a 31% increase in the number of operations
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performed over the preceding five years (2). Survival after
lung transplant has also been improving over the years (1).
Despite this, when compared to other solid-organ
transplants, lung transplant survival is substantially lower (1).
The survival curve following lung transplant, shows a steady
drop after the first-year of transplant (3,4). This has been
attributed to the development of chronic lung allograft
dysfunction (CLAD), which develops in 50% of grafts
at five years and has remained relatively stable over time
(1,4). CLAD encompasses multiple distinct phenotypes
with one of the main problematic types being bronchiolitis
obliterans syndrome (BOS) (5). This CLAD phenotype has
been specifically noted to be present in over 40% of lung
transplant recipients within five years, has a median onset
of 2.3 years, and has accounted for 27.5% of deaths in lung
transplant recipients from 1990 to 2017 (6-12).
The development of BOS has been hypothesized to occur
due to many factors, such as acute rejection, cytomegalovirus
infection, and ischemia-reperfusion injury (13).
Airway ischemia, inflammation, and subsequent necrosis
due to reduced oxygenated blood supply have also been
implicated in the development of progressive inflammation
and fibrosis-potentially leading to BOS. This could be
because following a typical lung transplantation; the lower
airways are perfused via minimal retrograde flow from the
pulmonary veins as the arterial flow from the bronchial
arteries is sacrificed in the transplantation process. A
permanent reduction in adequately oxygenated blood to the
pulmonary airways could thus increase the risk of chronic
ischemia and hypoxic damage (7,14-16).
Given this hypothesis, reducing lung ischemia in the early
post-transplant period could be of importance in order to
reduce the chances for development of late BOS; however,
a clear link between ischemia related airway anastomotic
problems and late BOS has not been found so far (17,18).
One proposed strategy, bronchial artery revascularization
(BAR), has been utilized as a surgical technique to
supply the airway with oxygenated blood (19,20). After
early implementation in specialized centers, BAR has
demonstrated promise in delaying the onset of BOS (20-23),
but has since not been implemented as standard of care
given its technically demanding nature and lack of extensive
experience with it. By revascularizing the bronchial arteries
through anastomosis of the donor bronchial artery to the
internal mammary artery or utilizing a saphenous vein graft
to form a new vascular conduit from the descending aorta,
direct ischemia to the airways is reduced. Early results from
uncontrolled single center studies in reduction of post-
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operative BOS development are encouraging (20-23).
In order to systematically analyze this technique, we
performed a systematic search and meta-analysis of
bronchial artery revascularization to assess its outcomes
and success following lung transplantation. We present the
following article in accordance with the PRISMA reporting
checklist (available at https://jtd.amegroups.com/article/
view/10.21037/jtd-22-213/rc).
Methods
Literature search strategy
An electronic search was performed in September 2019
using Ovid Medline, Cumulative Index of Nursing and
Allied Health Literature (CINAHL), Scopus and Cochrane
Controlled Trials Register (CCTR). To achieve maximum
sensitivity of the search strategy, combined terms such
as “lung”, “transplantation”, “transplant”, “bronchial”,
“artery”, “revascularization”, “BAR”, “lung transplantation”,
“bronchial artery revascularization”, “lung transplant”,
“en bloc double lung transplant”, “single lung transplant”,
“sequential lung transplant”, “lung transplant recipient”,
“right intercostobrachial artery”, “bronchial artery”,
“bronchial arteries”, “graft rejection”, “bronchiolitis
obliterans syndrome”, “internal thoracic artery”, “mammary
arteries”, “bronchial artery anastomosis” were used as either
keywords or MeSH terms. The reference lists of all eligible
studies were reviewed for further identification of potentially
relevant studies and assessed using the inclusion and exclusion
criteria.
Selection criteria
Eligible studies for the systematic review included all
articles discussing lung transplantation utilizing bronchial
artery revascularization. Articles were excluded if they
did not contain information regarding post-transplant
outcomes including development of BOS or survival. When
institutions published duplicate studies with overlapping
data, only the most complete reports with the longest
follow-up period were included for quantitative assessment.
Articles published from 1987 onwards were included.
Patients under the age of 16 were excluded. Studies not
published in the English language and those not involving
human subjects were excluded. Abstracts, case reports,
conference presentations, editorials, reviews, expert
opinions, and studies without adequate extractable data were
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Identification

Identification of studies via databases and registers

Records identified from Medline,
Scopus, CCTR, and CINAHL:
• Databases (n=219)
• Registers (n=0)

Included

Screening

Records screened
(n=33)

Records removed before screening:
• Duplicate records removed (n=36)
• Records marked as ineligible by
automation tools (n=0)
• Records removed due to lack of
population of interest (n=150)
Records excluded due to irrelevance,
missing information, or risk of data
duplication
(n=21)

Reports sought for retrieval
(n=12)

Reports not retrieved
(n=0)

Reports assessed for eligibility
(n=12)

Reports excluded:
• BAR technique not used (n=1)
• Insufficient data (n=2)
• Reviews (n=2)

Studies included in review
(n=7)
Reports of included studies
(n=7)

Figure 1 PRISMA flow diagram illustrating the search strategy. CCTR, Cochrane Controlled Trials Register; CINAHL, Cumulative Index
of Nursing and Allied Health Literature.

also excluded. A PRISMA diagram reflecting the search
strategy is demonstrated in Figure 1. Risk of bias assessment
was carried out using the Newcastle-Ottawa scale (NOS)
score (Tables S1,S2). A PRISMA 2020 checklist is provided
as supplementary material.
Data extraction and critical appraisal
Data were extracted from article texts, tables, and figures.
Discrepancies and disagreements were resolved by discussion,
consensus, and adjudication by a senior coauthor.

graphically displayed to visualize survival over time. Metaregression analysis was also done to assess the impact of
time on mortality. R software, version 3.6.0 (R Foundation
for Statistical Computing, Vienna, Austria) was used for
all data analysis and visualization. The meta-analysis was
performed using metafor package for R. P values less than
0.05 were considered statistically significant. This review
did not have a previously published protocol nor was it
registered. IRB approval was not required since publicly
available deidentified data was used for the study.
Results

Statistical analysis

Baseline study and patient characteristics

A binary outcome meta-analysis of proportions was
conducted for the available main perioperative and
postoperative variables with logit transformation.
Heterogeneity was evaluated using Cochran Q and the
I2 test. Survival data from each study were collected and
pooled to retrieve a weighted mean and 95% confidence
interval at specific time points. Such data were then

Seven studies comprising 143 patients were included in this
meta-analysis (20-26). Five of the studies comprising 105
patients were conducted from the year 1990 to 2000 (2023,26). Of the remaining two, one was conducted from
1993 to 2003 (25) while the other was from 2007 to 2010
(24). Additional details are presented in the supplementary
tables. The mean patient age was 47 (95% CI: 40–55)

© Journal of Thoracic Disease. All rights reserved.
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Table 1 Baseline characteristics and indications
Variable

Pooled value [95% CI]

Number of studies

Events/total (n/N)

Heterogeneity, (%)

Age, years

47 [40–55]

3

67

32

Male (%)

61 [48–72]

4

47/77

0

Single lung transplant (%)

27 [21–25]

7

39/143

0

Double lung transplant (%)

73 [65–79]

7

104/143

0

Emphysema (%)

71 [38–91]

3

57/79

36

Alpha-1 AT deficiency (%)

40 [2–96]

3

38/75

85*

Pulmonary fibrosis (%)

26 [4–75]

4

22/77

69*

Cystic fibrosis (%)

24 [0–100]

3

14/76

87*

6 [2–17]

3

5/84

0

Indications

Pulmonary HTN (%)

*, indicates significant heterogeneity, P<0.05. CI, confidence interval; AT, antitrypsin; HTN, hypertension.

years. 61% (95% CI: 48–72%) of patients were male. Of
all transplants, 73% (95% CI: 65–79%) were double lung
transplants while 27% (95% CI: 21–25%) were single lung
transplants. Indications for transplant included emphysema
[71% (95% CI: 38–91%)], alpha-1 antitrypsin deficiency
[40% (95% CI: 2–96%)], pulmonary fibrosis [26% (95%
CI: 4–75%), cystic fibrosis [24% (95% CI: 0–100%)], and
pulmonary hypertension [6% (95% CI: 2–17%)]. These
baseline characteristics are listed in Table 1.

A total of 91% (95% CI: 46–99%) of bronchial artery
revascularizations were performed using an internal mammary
artery conduit. Seven percent (95% CI: 1–51%) of the
remaining transplants were performed with a saphenous vein
graft as the conduit for bronchial artery revascularization. Of the
total patients, 89% (95% CI: 79–95%) underwent angiography
to evaluate bronchial artery revascularization. Ninety-three
percent (95% CI: 82–97%) of patients who underwent
angiography demonstrated successful bronchial artery
revascularization with contrast passing through the conduit. Of
these, 96% (95% CI: 94–97%) of patients utilizing an internal
mammary artery conduit had patent revascularization of the
bronchial artery. Eighty-seven percent (95% CI: 65–96%)
ultimately healed their tracheal anastomosis (Table 2).

9–38%) of patients while 14% (95% CI: 4–41%) of patients
required re-exploration due to bleeding complications.
18% (95% CI: 9–31%) of patients experienced bleeding
complications of any kind. Development of BOS or its
precursor, pre-BOS, was demonstrated in 19% (95%
CI: 8–37%) of patients. Cause of death was related to
respiratory failure in 8% (95% CI: 0–99%) of patients and
multi-organ failure in 6% (95% CI: 3–11%) of patients.
The mean follow-up time was 21 months (95% CI:
3–38 months) with a 30-day/in-hospital mortality of 6%
(95% CI: 3–11%). 79% (95% CI: 63–89%) of patients were
free from rejection at three months. Eighty-four percent
(95% CI: 49–97%) of patients were free from anastomotic
intervention at both three and six months. Eeighty-three
percent (95% CI: 29–98%) of patients were free from signs
of airway ischemia (assessed via bronchoscopy) at three
and six months (Table 3). Pooled survival analysis, seen in
Figure 2, demonstrates 87% (95% CI: 78–92%) and 71%
(95% CI: 46–87%) survival at one year and five years
respectively. Pooled freedom from bronchiolitis obliterans
is demonstrated in Figure 3 with 86% (95% CI: 77–91%)
of patients free from BOS at two years. A meta-regression
analysis to assess the relationship between Log 30-day/
in-hospital mortality and time (publication year), shown
in Figure 4, showed no significant effect of time on the
mortality outcome (P=0.58).

Postoperative outcomes and complications

Discussion

Re-operation for any reason was required by 20% (95% CI:

With the increasing number of lung transplants being

Perioperative characteristics

© Journal of Thoracic Disease. All rights reserved.
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Table 2 Peri-operative characteristics, outcomes, and complications
Variable

Pooled value [95% CI]

Number of studies

Events/total (n/N)

Heterogeneity (%)

91 [46–99]

7

123/143

72*

7 [1–51]

7

18/143

73*

93 [82–97]

6

116/133

7

Patent angiography, IMA conduit (%)

96 [94–97]

5

103/106

0

Fully healed tracheal anastomosis (%)

87 [65–96]

3

57/65

0

Re-exploration (any) (%)

20 [9–38]

5

24/125

50

Re-exploration due to bleeding (%)

14 [4–41]

3

11/80

0

Bleeding, all (%)

18 [9–31]

5

19/115

11

BOS/pre-BOS (%)

19 [8–37]

6

14/93

31

Respiratory failure (%)

8 [0–99]

2

3/45

0

Multi-organ failure (%)

6 [3–11]

4

4/77

0

Conduit type
Internal mammary artery (%)
Saphenous vein (%)
Patent angiography, any conduit (%)

Complications

Cause of death

*, indicates significant heterogeneity, P<0.05. CI, confidence interval; IMA, internal mammary artery; BOS, bronchiolitis obliterans
syndrome.

Table 3 Long-term outcomes
Variable

Pooled value [95% CI]

Number of studies

Events/total (n/N)

Heterogeneity, (%)

Follow up, months

21 [3–38]

4

70

94*

30-day/in-hospital mortality (%)

6 [3–11]

6

8/135

0

3 months

83 [29–98]

3

48/55

48

6 months

83 [29–98]

3

48/55

48

3 months

84 [49–97]

4

57/63

37

6 months

84 [49–97]

4

57/63

37

79 [63–89]

4

51/63

0

Freedom from airway ischemia (%)

Freedom from anastomotic intervention (%)

Freedom from rejection (%)
3 months

*, indicates significant heterogeneity, P<0.05. CI, confidence interval.

performed and a continual lagging median survival rate
when compared to other solid-organ transplants, the
field of lung transplantation has been hampered by the
long-term development of CLAD. In order to strive to
reach the survival rates attained by other solid-organ
transplants, strategies to mitigate development of BOS

© Journal of Thoracic Disease. All rights reserved.

must be developed. Whether through surgical technique or
medications, reducing BOS is of paramount importance to
lengthening the survival time of lung transplant recipients.
Given the hypothesis of ischemia in the early peri-operative
period potentially leading to late development of BOS, it
stands to reason that improvements in surgical technique
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−1
91

87

80

82

Survival, %

74

71

60
40
20
0
1

12

24

36

60

Months

Log 30-day/in-hospital mortality

100

P=0.58

Baudet

−2

Daly

−3

Yacoub
Pettersson '13

−4

Pettersson '97

−5
1990

Figure 2 Pooled survival of patients undergoing lung transplant

Bech

1995

2000

2005

2010

2015

Publication year

with bronchial artery revascularization. BOS, bronchiolitis

Figure 4 Meta-regression analysis between Log 30-day/in-hospital

obliterans syndrome.

mortality and time (publication year).

100

Freedom from BOS, %

94 93

80

88

86

67

60
40
20
0
0

3

6

12

24

36

Months

Figure 3 Demonstration of freedom from bronchiolitis obliterans
following bronchial artery revascularization.

may limit its development and therefore improve patient
survival. Following conventional lung transplantation
without bronchial artery revascularization, the recipient’s
lungs are dependent on collateral flow from the pulmonary
vein in the submucosal plexus with bronchial arterioles
and retrograde flow through these vessels (23,27,28).
Revascularization of the donor organ by recipient bronchial
arteries may take up to two to four weeks to restore flow
which represents a critical period for healing. Restoring
bronchial artery flow at the time of transplant could
potentially result in reduced early ischemia to the bronchial
anastomosis, improved overall survival, and reduced rates of
BOS development.
As a contributing factor to the development of BOS,

© Journal of Thoracic Disease. All rights reserved.

understanding airway ischemia and its effects on the
lung may be helpful in outlining the evolution of BOS
(6,7,13,15,16). In our study, 83% (95% CI: 29–98%) of
patients did not have any signs of airway ischemia following
bronchial artery revascularization at both three and
six months post-transplantation. This percentage is largely
consistent with the rate of airway complications following
conventional lung transplantation, reported as 15.7% in
a large scale study (29). The reported incidence of airway
complications with conventional lung transplantation
ranges from 2% to 33% and these complications vary in
their requirement for intervention, ranging from simple
conservative management to angioplasty, stenting, and
surgical intervention (30). In the BAR cohort, 84% (95%
CI: 49–97%) of patients were free from anastomotic
intervention at both three and six months. When comparing
this intervention rate with conventional lung transplantation,
14.6% of patients required stent insertion at an average of
76 days for anastomotic complications in a cohort of 123
conventional lung transplant patients (31). However, based
on these data, BAR has yielded similar airway ischemia and
airway intervention rates among lung transplant recipients
compared to conventional lung transplants.
While airway ischemia rates may be similar between
BAR and conventional lung transplant recipients, in order
to truly evaluate the results of the BAR cohort, long-term
survival needs to be examined. The United Network for
Organ Sharing (UNOS) reports overall survival percentages
for lung transplantation at 1-, 3-, and 5-year as 89.4%,
74.8%, and 61.2%, respectively (32). While these numbers
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include all types of lung transplant techniques, and given
that BAR is rarely performed, these percentages are then
more likely to represent conventional transplantation
without BAR. When comparing these survival rates with
those in our study, survival percentages at one year, three
years, and five years are 87%, 74%, and 71% respectively.
These numbers are similar at the one year and three year
mark, yet the survival at 5 years is almost 10% better in
the BAR cohort. One of the many possible reasons for this
difference could be CLAD (33) which has a median onset
of 2.3 years (12). It thus stands to reason that reduction in
CLAD may contribute to improved long term survival. This
is further supported by our data demonstrating 19% (95%
CI: 8–37%) of patients who underwent BAR developed
BOS or showed signs of pre-BOS over the mean follow
up period of 21 months (95% CI: 3–38 months). When
demonstrated as freedom from development of BOS, 67% of
patients had no signs of BOS at 36 months. In comparison,
approximately 43% of patients develop CLAD (without
subtype distinction) at a median time of 2.3 years (12).
This difference may suggest a correlation between BAR,
reduction of BOS development, and improved survival
outcomes. Further long-term data is needed to determine if
this difference is statistically significant.
While there may be benefits to patients following BAR
for lung transplantation, it is a demanding technique
requiring additional focus on conduit preservation and
monitoring of post-operative complications. Procuring the
donor organ requires additional meticulous preservation of
the bronchial artery and understanding of variant bronchial
artery anatomy. This additional understanding requires
further specialized training and has only been accomplished
in limited number of centers with expert surgeons.
Further, the additional preservation and formation of
an additional arterial anastomosis increases the risk of
bleeding complications and has been historically suggested
as a reason for increased operative and cardiopulmonary
bypass times (34). However, a propensity matched trial by
Pettersson et al. indicated similar cardiopulmonary bypass
time [BAR (n=20) vs. Non-BAR/Double lung (n=37):
164±32 vs. 178±78; P=0.3] and skin-to-skin times [BAR vs.
Non-BAR/Double lung: 350±71 vs. 318±86; P=0.07] (24).
Despite this smaller scale study, concerns persist regarding
the feasibility of BAR and its effect on short-term outcomes.
When evaluating the short-term success of BAR, the
two important factors to note are peri-operative mortality
and bleeding complications. In evaluation of peri-operative
mortality, when examining all transplants from 1989 to
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2014, the UNOS lung transplantation 30-day mortality
was 5.5% (35). In this cohort of BAR patients, the 30-day/
in-hospital mortality was 6% (95% CI: 3–11%). These
mortality rates are similar given the UNOS-reported overall
rate is within the 95% confidence interval from our pooled
cohort. With respect to bleeding complications in our study,
18% (95% CI: 9–31%) of patients suffered a hemorrhage
of any kind with 14% (95% CI: 4–41%) requiring reoperation due to bleeding. Re-exploration for any cause was
seen in 20% (95% CI: 9–38%) of patients. In comparison,
a study of 224 patients undergoing conventional lung
transplantation revealed a hemorrhage rate of 25.3% while
re-operation for bleeding was required in 5.8% of patients.
In this series, reoperation was needed in 7.2% of patients.
Therefore, re-operation for bleeding and re-operation
for any reason were higher in our cohort of patients with
BAR, while overall hemorrhage rates were similar in both
groups (36). Previous studies have thus listed risk of
bleeding from revascularization sites as a potential
complication from the BAR procedure and this is reflected
in our systematic review too (23,24).
In evaluating BAR, surgeons should compare the
increased technical requirements and peri-operative
bleeding complications with the potential reduction
or delay of BOS onset, which may outweigh the
complications (20,24,26). It is possible that advancement
in lung transplantation techniques and policies may
have resulted in the improved overall survival after
lung transplantation. By extension, it can be argued
that BOS rates may also have improved (8,37).
However, our results showed no effect of time on the
30-day/in-hospital mortality. It is also possible that offsetting
the period of early ischemia following transplantation
can reduce BOS and improve survival times. Despite this
theoretical difference, freedom from airway ischemia and
airway intervention was similar between BAR and non-BAR
patients. Further long-term, large-scale analysis is needed
to determine if the reduction in BOS development and
improvement in long-term survival remain true for BAR.
Limitations and future directions
This systematic review and meta-analysis is limited by the
available surgeons, institutions, and papers discussing a
highly specialized technique. Given these limited numbers,
direct evaluation via double-armed studies comparing BAR
to similarly matched non-BAR patients was not possible,
and therefore the technique was compared to overall
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numbers as cited by UNOS. Further, as the surgeons and
centers who performing BAR are likely invested in its
positive portrayal, they may be subject to some selection
and publication bias. This systematic review indicated many
positive aspects of utilizing BAR in lung transplantation and
provided early signs of high survival, low development of
BOS, and low interventions for airway ischemia. However,
long-term studies directly comparing similar patients
undergoing BAR and non-BAR lung transplantation are
needed to further evaluate BAR’s effect on outcomes
relative to conventional transplantation. While it is possible
for double lung transplant patients to undergo a tracheal
anastomosis with a left bronchial artery revascularization,
analysis of included papers shows lack of sufficient
granularity to differentiate that. Additionally, for the sake of
this review the single-lung transplant patients were assumed
to have undergone unilateral BAR with no subsequent
contralateral single-lung transplant with contralateral BAR.
The promising nature of this intervention will require a
more granular study of sequential bilateral single-lung
transplant with bilateral BAR versus double-lung transplant
with bilateral BAR as well as double-lung transplant with
unilateral BAR. However, it should be noted that the
literature on survival differences between single vs. double
lung transplantation is still conflicting (38,39). Donation
after circulatory death (DCD) is another aspect that would
be worth investigating. Lung transplant outcomes are
generally comparable between DCD and Donation after
Brainstem Death (DBD) (40); however, a higher rate of BOS
following DCD lung transplantation has been reported (41).
These conflicting results warrant further investigation
into the relationship, if any, between airway ischemia and
development of BOS. Given that, DCD has been gaining
gradual acceptance, and that the studies included in this
analysis span the last three decades, not much information
was available to analyze this. Future comparative studies on
BAR with results stratified by donor type (DCD vs. DBD)
would help in answering such questions. Further, due to
the technical requirements, all surgeons participating in a
comparative study should be adequately trained at centers
with extensive experience in BAR, otherwise, true results
may be masked by imperfect technique.

obliterans, and low early anastomotic intervention due
to ischemia at the cost of increased short-term bleeding
complications. Further comparative analysis should be
performed to evaluate this surgical technique versus
conventional lung transplant.
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Table S1 Characteristics of studies included in the meta-analysis
Title

Authors

Year
Institution
published

Journal

Study type

Study
date(s)

New-Castle
Total
Ottawa Scale
patients
Score

Comparative study of bronchial Pettersson et al.
artery revascularization in lung
transplantation

2013

Dept of Thoracic and Cardiovascular
Surgery, Cleveland Clinic

Cardiothoracic
Transplantation

Retrospective 2007–2010

27

7

Long-term outcome of lung
transplantation for cystic
fibrosis-Danish results

Bech et al.

2004

Dept of Cardiothoracic Surgery,
Rigshospitalet, Copenhagen University
Hospital, Copenhagen

European Journal Retrospective 1993–2003
of Cardio-thoracic
Surgery

11

6

Bronchial artery
revascularization improves
tracheal anastomotic healing
after lung transplantation

Hyytinen et al.

2000

Depts of Thoracic and Cardiovascular
Surgery, Pulmonary Medicine and
Radiology, Helsinki University Central
Hospital, Helsinki, Finland

Scandinavian
Cardiovascular
Journal

Retrospective 1992–1997

8

7

Direct bronchial artery
revascularization and en bloc
double lung transplantation—
surgical techniques and early
outcome

Pettersson et al.

1997

Dept of Thoracic Surgery RT, Diagnostic The Journal of
Radiology and Medicine, The national
Heart and Lung
University Hospital Copenhagen
Transplantation
Denmark

Retrospective 1992–1995

47

6

Medium term results of
Yacoub et al.
direct bronchial arterial
revascularisation using IMA for
single lung transplantation (SLT
with direct revascularisation)

1997

Harefield Hospital, Harefield, Middlesex European Journal Retrospective 1991–1993
United Kingdom
of Cardio-thoracic
Surgery

22

6

Intermediate-term results
Baudet et al.
after en bloc double-lung
transplantation with bronchial
arterial revascularization.
Bordeaux Lung and Heart-Lung
Transplant Group

1996

Dept of Cardiovascular and Pediatric
Cardiac Surgery, Bordeaux Heart
Hospital, a Dept of Surgery, HautLeveque Hospital, Dept of Cardiac
and Vascular Surgery, Bordeaux Heart
Hospital, Bordeaux-Pessac, France
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6

Routine immediate direct
Daly et al.
bronchial artery revascularization
for single-lung transplantation

1994

Section of Cardiac Surgery, Mayo Clinic Annals of Thoracic Retrospective
Surgery
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6
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Table S2 Newcastle-Ottawa Scale (NOS) scoring system to assess risk of bias for the studies included

Study name

Outcome of
Comparability of
Was follow-up
Representatives Selection of the
Total quality
Ascertainment
interest
cohorts on the
Assessment long enough Adequacy of
of the exposed non-exposed
score
of exposure
Was not present bases of the design of outcome for outcome to follow-up
cohort
cohort
(out of 9)
at start of study
or analysis
occur

Comparative study
of bronchial artery
revascularization in lung
transplantation

1

1

1

1

0

1

1

1

7

Long-term outcome of lung
transplantation for cystic
fibrosis - Danish results

1

0

1

1

0

1

1

1

6

Bronchial artery
revascularization improves
tracheal anastomotic healing
after lung transplantation

1

1

1

1

0

1

1

1

7

Direct bronchial artery
revascularization and en bloc
double lung transplantation—
surgical techniques and early
outcome

1

0

1

1

0

1

1

1

6

Medium term results of
direct bronchial arterial
revascularisation using
IMA for single lung
transplantation (SLT with
direct revascularisation)

1

0

1

1

0

1

1

1
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1
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1
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revascularization for singlelung transplantation
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